Submission of Stem Cell Transplant Data to CIBMTR and NMDP

This study is currently recruiting participants.
Verified June 2012 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00923585
First received: June 17, 2009
Last updated: May 1, 2013
Last verified: June 2012
  Purpose

Background:

  • A federal government mandate requires stem cell transplant centers to collect and maintain in a database a minimum of information regarding transplant recipients and their donors.
  • The National Marrow Donor Program (NMDP) and the Center for International Blood and Marrow Transplant Research (CIBMTR) maintain an extensive database of medical information on transplant donors and recipients and conducts research using this information.
  • Information collected under this study will be submitted to NMDP/CIBMTR in response to the federal mandate.

Objectives:

  • To learn more about what makes stem cell transplants work well, such as determining the following:
  • how well recipients recover from their transplant
  • how recovery after a transplant can be improved
  • how access to transplant for different groups of patients can be improved
  • how well donors recover from the collection procedures

Eligibility:

- Patients enrolled in an NIH stem cell transplant protocol.

Design:

  • Patients are asked to give informed consent to participate in the study before starting pre-transplant conditioning.
  • Donors are asked to give informed consent to participate before starting preparation for stem cell collection begins.
  • Patients and donors who do not wish to participate will still have a minimum set of data submitted, as required by law, but the information obtained will not be used in research.

Condition
Autologous Stem Cell Transplantation
Allogeneic Stem Cell Transplantation
Solid Tumors
Blood Cancers

Study Type: Observational
Official Title: Autologous and Related Allogeneic Hematopoietic Stem Cell Transplant Data Submission to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP)

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 500
Study Start Date: December 2008
Detailed Description:

Background:

  • In 2005, the United States Congress legislated that outcome data would be collected on all patients who have been recipients of a stem cell therapeutics product (including bone marrow, cord blood, or other such product) from a donor. The Health Services and Resources Administration (HRSA) awarded the contract for this Stem Cell Therapeutic Outcomes Database (SCTOD) to the Center for International Blood and Marrow Transplantation (CIBMTR). The CIBMTR is thus responsible for the administration of this activity and collection and analysis of the data. The CIBMTR was established in 2004 as an affiliation between the National Marrow Donor Program (NMDP) and the Medical College of Wisconsin.
  • NCI - ETIB and POB, in order to comply with the SCTOD requirements, will participate in the CIBMTR Outcomes Data Reporting process for all autologous and related allogeneic hematopoietic cell therapy recipients and donors. Patients receiving unrelated donor cell therapies will participate in a separate data collection protocol designed to satisfy the requirements for participation as an NMDP transplant center as well as the SCTOD reporting.

Objectives:

- To meet the reporting requirements of the Stem Cell Therapeutic Outcomes Database.

Eligibility:

- All patients receiving autologous or related allogeneic hematopoietic stem cell transplants will be eligible regardless of age, diagnosis, or disease status.

Design and Modifications from CIBMTR protocol:

  • Patients will be consented prior to the start of their pre-transplant conditioning regimen.
  • Related donors will be consented prior to the start of their mobilization or, if no mobilization, prior to the date of cell collection.
  • Patients and donors who do not wish to participate will still have a minimum set of data submitted, as required by law. However, this data will not be used in research.
  • For privacy concerns, the following data will not be collected or reported: Social Security Number (SSN), Mother's Maiden Name, Country of birth, Median household income, Education and Occupation. This data may be omitted without affecting compliance with the SCTOD. All other demographic data collected at NIH will be stored separate from the research records in a locked cabinet accessible only to those with roles directly related to reporting the data.
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • Eligibility to Participate in the Research Database

Recipient Eligibility Criteria:

Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children.

Individual with Marrow Toxic Injury Eligibility Criteria:

Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR.

Unrelated Donor Eligibility Criteria:

All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database.

All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00923585

Contacts
Contact: Zetta A Blacklock-Schuver, R.N. (301) 451-6569 bblacklock@mail.nih.gov
Contact: Ronald E Gress, M.D. (301) 496-1791 gressr@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office     (888) NCI-1937        
Sponsors and Collaborators
Investigators
Principal Investigator: Ronald E Gress, M.D. National Cancer Institute (NCI)
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00923585     History of Changes
Other Study ID Numbers: 090053, 09-C-0053
Study First Received: June 17, 2009
Last Updated: May 1, 2013
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Data Collection
CIBMTR
NMDP
Stem Cell Transplantation

Additional relevant MeSH terms:
Hematologic Neoplasms
Neoplasms by Site
Neoplasms
Hematologic Diseases

ClinicalTrials.gov processed this record on May 19, 2013